New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
May 22, 2015
12:39 EDTCICigna May June volatility elevated
Cigna June call option implied volatility is at 29, July is at 26, October is at 27; compared to its 52 week range of 16 to 31, suggesting large near term price movement.
May 21, 2015
20:04 EDTMDTMedtronic CEO sees untapped potential in India, Times of India says
Subscribe for More Information
May 20, 2015
09:34 EDTMDTMedtronic announces new data for drug-coated balloon
Subscribe for More Information
08:09 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
07:42 EDTAETAetna removed from US Focus List at Credit Suisse
Subscribe for More Information
07:16 EDTSTJ, MDTLeerink to hold a booth tour at EuroPCR
Subscribe for More Information
05:31 EDTBSXNew study evaluating Boston Scientific Lotus Valve System shows low PVL rates
Subscribe for More Information
05:29 EDTSTJSt. Jude Medical announces preliminary results from ILUMIEN I and ILUMIEN II
St. Jude Medical announced preliminary results from the ILUMIEN I trial and final results from the ILUMIEN II clinical study. Taken together, the findings from both studies show that with resolution up to 10 times higher than intravascular ultrasound, optical coherence tomography imaging can help improve stent selection and deployment, better support clinical decision-making and improve patient outcomes. In the prospective study to date examining OCTís impact on clinical decisions and their associated outcomes, ILUMIEN I assessed 418 patients suffering stable or unstable angina or non-ST segment elevation myocardial infarction. The studyís 12-month data shows: OCT guidance conducted either pre- or post-PCI altered physician decision-making in 65% of patients; Pre-PCI OCT altered treatment planning in 55% of patients and led to changes in decisions related to stent length and diameter; OCT imaging was associated with a reduction of in-hospital MI when used pre- and post-PCI to change the procedural strategy. The ILUMIEN II study was designed to determine whether OCT guidance results in a comparable degree of stent expansion as IVUS imaging. After an analysis of OCT-guided stenting or IVUS-guided stenting in 940 patients from the ILUMIEN I and ADAPT-DES studies, the degree of stent expansion was found to be comparable between OCT and IVUS imaging. The studyís data shows OCT and IVUS guidance were also associated with comparable rates of major stent malapposition, tissue protrusion and stent edge dissection.
May 19, 2015
12:05 EDTMOHMolina Healthcare moves up following a positive Navellier mention
Subscribe for More Information
12:04 EDTAET, CI, HUMAnthem CFO says 'good time' for 'meaningful' acquisition, Reuters reports
Subscribe for More Information
08:40 EDTMDTMedtronic sees FY15 revenue $20.3B, may not compare to consensus $28.15B
Subscribe for More Information
08:40 EDTMDTMedtronic sees Q4 adjusted EPS at upper half of $1.08-1.13, consensus $1.10
Subscribe for More Information
08:05 EDTSTJSt. Jude Medical announces Canadian launch of Prodigy Chronic Pain System
Subscribe for More Information
07:54 EDTBSXBoston Scientific reports positive data from EVOLVE trial
Subscribe for More Information
May 18, 2015
09:33 EDTAETAetna repeats FY15 operating EPS view $7.20-$7.40, consensus $7.38
Subscribe for More Information
09:27 EDTMDTMedtronic announces study results showing CRT system optimizes treatment
Subscribe for More Information
May 15, 2015
16:51 EDTAETGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
16:07 EDTMOHMolina Healthcare to acquire certain Michigan assets of HealthPlus
Subscribe for More Information
14:20 EDTSTJSt. Jude Medical reports positive results from CardioMEMS HF System
Subscribe for More Information
14:01 EDTSTJSt. Jude Medical reports positive results from Allure Quadra CRT-P System
St. Jude Medical announced the presentation of important data supporting the first and only quadripolar cardiac resynchronization therapy pacemaker system in the U.S., during the Heart Rhythm Society's 36th annual scientific sessions. The Allure Quadra CRT-P system, with the Quartet Quadripolar LV Lead is associated with a 63% reduction in the need to replace the lead or deactivate CRT following implant. Quadripolar LV pacing using SJM quadripolar CRT-Ds or CRT-Ps and an SJM quadripolar lead provides physicians with multiple pacing options to avoid phrenic nerve stimulation and allow for optimal treatment delivery without the need to replace or deactivate the therapy. An analysis evaluating more than 3,000 patients implanted with a CRT-P (1,325 with a quadripolar lead vs. 1,930 with a bipolar lead) looked at whether the known decreased need to replace or deactivate LV leads associated with SJM quadripolar CRT-Ds and the Quartet LV lead also extends to St. Jude Medical quadripolar CRT-Ps. The retrospective data analysis was presented in a session titled Quadripolar Leads are Associated with Fewer LV Lead Replacements and Deactivations in CRT-P Patients by Dr. Mintu P. Turakhia, who led the investigation. The data show that patients with the Quartet LV lead were 63% less likely to undergo lead replacement or deactivation of CRT compared to the patients with bipolar leads.
13:33 EDTMDTMedtronic: TYRX antibacterial envelope reduces cardiac device infection rates
Subscribe for More Information
11:08 EDTHUMOmega Advisors gives quarterly update on stakes
NEW STAKES: Targa Resources (TRGP), Targa Resources Partners (NGLS), Humana (HUM), Dow Chemical (DOW), and Twenty-First Century Fox (FOXA). INCREASED STAKES: Kinder Morgan (KMI), Chimera Investment Corporation (CIM), AerCap Holdings (AER), Shire (SHPG), and KKR & Co. (KKR). DECREASED STAKES: eBay (EBAY), Altisource Portfolio Solutions (ASPS), Caesars Entertainment (CZR), Navient (NAVI), and TerraForm Power (TERP). LIQUIDATED STAKES: HCA Holdings (HCA), Gilead (GILD), Cabot Oil & Gas (COG), and Apple (AAPL).
10:29 EDTBSXAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTBSXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:45 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
08:41 EDTSTJSt. Jude Medical management to meet with Leerink
Subscribe for More Information
08:12 EDTMDTMedtronic Micra TPS meets initial safety, performance measures
Subscribe for More Information
07:32 EDTWCGWellCare valuation compelling after selloff, says Leerink
Leerink views the valuation of WellCare shares as compelling following the company's "solid" Q1 results. The firm reiterates an Outperform rating on the stock with a $105 price target.
May 14, 2015
13:34 EDTMDTMedtronic: Micra transcatheter pacemaker meets initial safety measures in study
Subscribe for More Information
13:31 EDTMDTMedtronic says Evera MRI ICD study meets safety, efficacy endpoints
Subscribe for More Information
09:41 EDTBSX, STJ, MDTLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
07:33 EDTUNHUnitedHealth would consider Optum spinoff if benefits erode, says UBS
Subscribe for More Information
May 13, 2015
11:22 EDTHUMOptions with increasing implied volatility
Subscribe for More Information
10:18 EDTCI, AET, HUMAnalyst says sell Humana amid 'wishful' takeover speculation
Subscribe for More Information
10:01 EDTHUMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:08 EDTSTJSt. Jude Medical receives CE Mark approval of Ellipse expanded labeling
Subscribe for More Information
07:31 EDTBSX, STJHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
06:12 EDTCI, HUMHumana downgraded to Underperform from Neutral at Sterne Agee CRT
Sterne Agee CRT analyst Brian Wright downgraded Humana (HUM) to Underperform saying speculation about a takeover is "wishful thinking" at current share levels. The stock rallied 4% yesterday after Leerink told investors that Aetna (AET) may acquire Humana or Cigna (CI) in the near-term. Wright also sees "material" risk to Humana's earnings guidance risk with paid claims outpacing premium growth. He lowered his price target for shares to $150 from $165. Humana shares closed yesterday up $6.76 to $173.38.
May 12, 2015
15:46 EDTHUMHumana May volatility increases on sharp rally
Subscribe for More Information
15:39 EDTCICigna May volatility elevated
Cigna May call option implied volatility is at 35, June is at 28, and August is at 30; compared to its 90-day average of 31, suggesting large near term price movement.
13:03 EDTAETAetna repeats view of FY15 operating EPS $7.20-$7.40, consensus $7.38
Subscribe for More Information
11:53 EDTHUM, CI, AETAnalyst predicts large transaction 'imminent' for Aetna
Subscribe for More Information
10:28 EDTHUMOptions with increasing implied volatility: YELP HUM LULU CTRX
Subscribe for More Information
10:04 EDTHUM, AETHigh option volume stocks
Subscribe for More Information
10:02 EDTMDTMedtronic receives FDA approval and CE Mark for Advance ST cryoballoon
Subscribe for More Information
09:53 EDTAET, HUMAetna merger with Cigna or Humana likely 'imminent,' says Leerink
Subscribe for More Information
07:35 EDTSTJ, HNTBofA/Merrill to hold a conference
Subscribe for More Information
05:23 EDTBSXNevro announces filing of petitions for inter partes review by Boston Scientific
Subscribe for More Information
May 11, 2015
15:06 EDTAETAetna backs FY15 operating EPS $7.20-$7.40, consensus $7.38
In a regulatory filing earlier, Aetna reported that during upcoming investor meetings in May, the company expects to reaffirm its FY15 operating EPS guidance of $7.20-$7.40. Current FY15 EPS consensus is $7.38.
07:40 EDTUNHFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertexís Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasnít announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
07:22 EDTWCGWellCare recent selloff presents buying opportunity, says Susquehanna
Subscribe for More Information
07:13 EDTUNHUnitedHealth management to meet with UBS
Subscribe for More Information
06:51 EDTAETAetna management to meet with Leerink
Meeting to be held in Hartford, CT on May 11 hosted by Leerink.
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use